Myelofibrosis Clinical Trials

A listing of 43 Myelofibrosis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Myelofibrosis

1 - 12 of 43

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 43 active clinical trials seeking participants for Myelofibrosis research studies. The states with the highest number of trials for Myelofibrosis participants are Texas, New York, California and Ohio.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Featured Trial

High Triglyceride Clinical Research Study

Recruiting

Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.

Conditions:

High Triglycerides

High Triglyceride Level

Hypertriglyceridemia

Elevated Triglycerides

Triglycerides High

Learn More

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT03878199

Recruiting

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Givi... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/11/2024

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +2 locations

Conditions: Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia

Learn More ›

A Safety and Tolerability Study of Jaktinib

NCT05279001

Recruiting

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/19/2024

Locations: Site 01, Canton, Ohio

Conditions: Myelofibrosis

Learn More ›

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847

Recruiting

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/20/2025

Locations: University of Alabama At Birmingham, Birmingham, Alabama +51 locations

University of Alabama At Birmingham, Birmingham, Alabama

University of Colorado Cancer Center, Aurora, Colorado

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

Emory University-Winship Cancer Institute, Atlanta, Georgia

University of Iowa Hospital and Clinics, Iowa City, Iowa

Washington University School of Medicine, Saint Louis, Missouri

Rutgers Cancer Institute of Nj, New Brunswick, New Jersey

Roswell Park Cancer Institute, Buffalo, New York

Nyu Langone Health � Long Island Hospital, Mineola, New York

Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York

Weill Medical College of Cornell University, New York, New York

University of North Carolina At Chapel Hill, Chapel Hill, North Carolina

University of Cincinnati Cancer Institute, Cincinnati, Ohio

Ohio State University, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas

Md Anderson Cancer Center, Houston, Texas

Oncology Consultants, Houston, Texas

Huntsman Cancer Institute At University of Utah, Salt Lake City, Utah

Seattle Cancer Care Alliance, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

Princess Margaret Cancer Center, Toronto, Ontario

McGill University Jewish General Hospital, Montreal, Quebec

St Paul'S Hospital, Vancouver, Not set

Peking Union Medical College Hospital, Beijing, Not set

Nanfang Hospital_Southern Medical University, Guangzhou, Not set

The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu), Hangzhou, Not set

Henan Cancer Hostipal, Zhengzhou, Not set

Helsinki University Central Hospital, Helsinki, Not set

Aou Policlinico S. Orsola-Malpighi Bologna&Nbsp;, Bologna, Not set

Azienda Ospedaliero-Universitaria Careggi (Aouc), Firenze, Not set

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori, Meldola, Not set

Fondazione Irccs Ca Granda Ospedale Maggiore, Milan, Not set

Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Orbassano, Not set

Azienda Policlinico Umberto 1 Universita Sapienza Di Roma, Rome, Not set

Centro Ricerche Cliniche Di Verona, Verona, Not set

Fujita Health University Hospital, Aichi, Not set

Chiba University Hospital, Chiba, Not set

National Cancer Center Hospital East, Chiba, Not set

University of Yamanashi Hospital, Chuo, Not set

Kyushu University Hospital, Fukuoka, Not set

Kumamoto Shinto General Hospital, Kumamoto, Not set

Radboud University Nijmegen Medical Center, Nijmegen, Not set

Hospital Universitari Germans Trias I Pujol, Badalona, Not set

Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen de La Arrixaca, Murcia, Not set

Hospital Clinico Universitario de Salamanca, Salamanca, Not set

United Lincolnshire Hospitals, Boston, Not set

Lincoln County Hospital, Lincoln, Not set

The Christie Nhs Foundation Trust Uk, Manchester, Not set

University of Oxford, Oxford, Not set

Conditions: Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, ET (Essential Thrombocythemia)

Learn More ›

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156

Recruiting

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/11/2025

Locations: University of California-San Diego/Moores UCSD Cancer Center, La Jolla, California +215 locations

University of California-San Diego/Moores UCSD Cancer Center, La Jolla, California

UCLA David Geffen School of Medicine, Los Angeles, California

Smilow Cancer Center at YNHH, New Haven, Connecticut

Clermont Oncology, Clermont, Florida

BRCR Medical Center Inc, Plantation, Florida

University of South Florida, Tampa, Florida

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Goshen Center for Cancer Care, Goshen, Indiana

Norton Cancer Institute, Louisville, Kentucky

Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Maryland Oncology Hematology, Rockville, Maryland

Michigan Cancer Specialists, Roseville, Michigan

Oncology Hematology Associates, Springfield, Missouri

Nebraska Cancer Specialists, Omaha, Nebraska

Cancer Care Specialists of Reno, Reno, Nevada

Hematology-Oncology Associates of Central New York (HOACNY), East Syracuse, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Duke University Medical Center, Durham, North Carolina

Gabrail Cancer Center, Canton, Ohio

Ohio Health, Columbus, Ohio

Taylor Cancer Research Center, Maumee, Ohio

Oregon Oncology Specialists, Salem, Oregon

Cancer Care Associates of York, York, Pennsylvania

Sanford Health, Sioux Falls, South Dakota

Avera Cancer Institute, Sioux Falls, South Dakota

Prairie Lakes Health Care System, Inc., Watertown, South Dakota

The University of Texas MD, Houston, Texas

Oncology Consultants, Houston, Texas

Community Cancer Trials of Utah, Ogden, Utah

Utah Cancer Specialists, Salt Lake City, Utah

Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia

Northwest Medical Specialties PLLC, Tacoma, Washington

Northwest Specialits, Tacoma, Washington

Hospital Aleman, Ciudad de Buenos Aires, Buenos Aires

Sanatorio de la Mujer, Rosario, Santa Fe

Sanatorio Allende, Córdoba, Not set

Royal North Shore Hospital, St Leonards, New South Wales

Royal Brisbane and Women's Hospital, Herston, Queensland

Royal Hobart Hospital, Hobart, Tasmania

Epworth Healthcare, Richmond, Victoria

Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel, Wein, Burgenland

Krankenhaus der Elisabethinen, Linz, Oberösterreich

Kepler Universitätsklinikum Gm, Linz, Oberösterreich

Klinikum Wels-Grieskirchen GmbH, Wels, Oberösterreich

UZ Antwerpen, Edegem, Antwerpen

Centre Hospitalier de Jolimont, Haine-Saint-Paul, Hainaut

CHU De Liège, Liege, Liège

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

Zna - Campus Middelheim, Antwerpen, Not set

ZNA Stuyvenberg Antwerpen, Antwerpen, Not set

AZ Klina, Antwerpen, Not set

Universitair Ziekenhuis Brussel - Myeloom Centrum Brussel (MCB), Jette, Not set

Centro de oncologia Leonardo da Vinci, Fortaleza, Ceará

Hospital das Clínicas UFG, Goiânia, Goiás

Hospital Erasto Gaertner, Curitiba, Paraná

Hospital de Clinicas de Porto Alegre - UFRGS, Porto Alegre, Rio Grande Do Sul

Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa LTDA, Porto Alegre, Rio Grande Do Sul

CEPON Centro de Pesquisas Oncologicas SC, Florianópolis, Not set

Instituto de Educação, Pesquisa e Gestão em Saúde, São Paulo, Not set

Hospital Israelita Albert Einstein, São Paulo, Not set

Fundacao Doutor Amaral Carvalho / Hospital Amaral Carvalho, São Paulo, Not set

Hospital A.C.Camargo Cancer Center - Clinical Oncology, São Paulo, Not set

UMHAT "Dr. Georgi Stranski", Pleven, Not set

UMBAL Sveti Georgi, Plovdiv, Not set

Specialized Hospital for Active Therapy of Hematological dis, Sofia, Not set

Oncologos del Occidente S.A, Pereira, Risaralda

Hospital Pablo Tobon Uribe, Antioquia, Not set

Centro Medico Imbanaco de Cali S.A., Cali, Not set

FOSCAL, Floridablanca, Not set

Odense University Hospital - Hematology, Odense, Not set

Institut de cancérologie du Gard - Hematologie clinique, Nimes Cedex 09, Gard

CHU Bretonneau, Tours, Indre-et-Loire

Hopital Bicetre, Paris, Le Kremlin-Bicêtre

CHU de Limoges Dupuytren, Haute-Vienne, Limoges

CHU De Nantes - HÃ©matologie C, Nantes, Loire-Atlantique

CHU de Nice - Hopital de l'Archet II - Pharmacie, Nice, Nice Cedex 3

Hospital CENTRE HOSPITALIER AVIGNON, Avignon cedex, Provence-Alpes-Côte-d'Azur

Centre Hospitalier Lyon, Pierre-benite, Rhône-Alpes

CHU de Saint Etienne, Loire, Saint Priest En Jarez

Centre Hospitalier Du Mans - Cancérologie Médicale, Le Mans, Sarthe

Hopital Avicenne - HÃ©matologie Clinique, Bobigny, Seine-Saint-Denis

CHRU Brest - Hôpital Morvan, Brest cedex, Not set

CHU - HÃ´pital Saint Louis - Centre D'Investigations Cliniq, Paris, Not set

Hopital Cochin - Aphp Hôpitaux Universitaires Paris Centre, Paris, Île-de-France

LTD Israeli-Georgian Medical R, Tbilisi, Not set

M.Zodelava Hematology Center L, Tbilisi, Not set

J.S.C."K.Eristavi National Cen, Tbilisi, Not set

Multi Profile Clinic Consilium, Tbilisi, Not set

Ltd "Medinvest - Institute of Hematology and Trans, Tbilisi, Not set

Universitätsklinikum Mannheim - University of Heidelberg, Mannheim, Baden-Württemberg

Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg

Universitätsklinikum Carl Gust, Dresden, Hamburg

Klinikum Kempten-Oberallgaeu GmbH, Kempten, Rheinland-Pfalz

Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Sachsen-Anhalt

Universitätsklinikum Leipzig AöR, Leipzig, Sachsen

Universitätsklinikum Schleswig, Kiel, Schleswig-Holstein

Semmelweis Egyetem - III. sz., Budapest, Not set

Dél-pesti Centrumkórház Ország, Budapest, Not set

Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András, Nyíregyháza, Not set

Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz -, Székesfehérvár, Not set

All India Institute of Medical Sciences, Dept. of Hematology, New Delhi (All India Institute Of Medical Sciences), New Delhi, Delhi

Sir Ganga Ram Hospital, New Delhi, Delhi

Nirmal Hospital - Hematology, Surat, Gujarat

St. John's Medical College Hospital, Bangalore, Karnataka

Fortis Hospital 154/9, Bengaluru, Karnataka

Fortis Memorial Research Institute, Gurgaon, New Delhi

All India Institute of Medical Sciences, Bhubaneswar, Orissa

Nilratan Sircar Medical College, Kolkata, West Bengal

Narayana Hrudayalaya Hospital, Hyderabad, Not set

Deenanath Mangeshkar Hospital & Research Center, Pune, Not set

Sahyadri Specialty Hospital, Pune, Not set

Assuta Ashdod University Hospi, Ashdod, HaDarom

Barzilai Medical Center, Ashkelon, HaDarom

Kaplan Medical Center, Rehovot, HaMerkaz

Shamir Medical Center (Assaf Harofeh), Zerifin, HaMerkaz

Western Galilee Hospital - Nahariya, Nahariya, HaZafon

Tel Aviv Sourasky Medical Cent, Tel Aviv, Tel-Aviv

Hadassah Medical Organization, Jerusalem, Yerushalayim

Soroka Medical Center - Hematology Institute, Beersheba, Not set

Bnai Zion Medical Center, Haifa, Not set

Carmel MC, Haifa, Not set

Arcispedale S.Anna - Ematologi, Cona, Ferrara

Istituto Clinico Humanitas Roz, Rozzano, Milano

AOU San Luigi Gonzaga, Orbassano, Torino

PO Civile SS.Antonio e Biagio, Alessandria, Not set

A.O.di Bologna Policl.S.Orsola, Bologna, Not set

Presidio Ospedaliero Garibaldi, Catania, Not set

AOU Careggi, Firenze, Not set

IRCCS Ospedale Policlinico San Martino, Genova, Not set

Clinica Ematologica, Univ. Deg, Genova, Not set

Irccs Irst, Meldola, Not set

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Not set

Ospedale San Raffaele, Milano, Not set

ASST Grande Ospedale Metropoli, Milano, Not set

Azienda Ospedaliera San Gerard, Monza, Not set

AOU Federico II, Napoli, Not set

Ospedale Civile S.Maria delle Croci, AUSL Ravenna, Ravenna, Not set

Arcispedale S Maria Nuova, AO di Reggio Emilia, Reggio Calabria, Not set

Azienda Ospedaliera Bianchi-Me, Reggio Calabria, Not set

AUSL di Rimini Ospedale Infermi di Rimini, Rimini, Not set

ASL Roma 2 - PO "S. Eugenio", Roma, Not set

Policlinico Universitario Agostino Gemelli, Roma, Not set

AOU Città della Salute e della Scienza di Torino, Torino, Not set

Ospedale di Circolo, PO Varese, Varese, Not set

Ospedale S.Bortolo, AULSS n.6, Vicenza, Not set

Inje University Busan Paik Hos, Busan, Busan Gwang'yeogsi [Pusan-Kwangyokshi]

Inje University Haeundae Paik Hospital, Busan, Busan Gwang'yeogsi [Pusan-Kwangyokshi]

Kyungpook National University Hospital - Hematolog, Daegu, Daegu Gwang'yeogsi [Taegu-Kwan]

National Cancer Institute Center for Cancer Research, Goyang-Si, Gyeonggido

Gachon University Gil Medical Center, Incheon, Incheon Gwang'yeogsi [Inch'n-Kwangyokshi]

Korea University Anam Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Gangnam Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Seoul National University Hospital - Department of Internal, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Pusan National University Hospital - Hematology and Oncology, Busan, Not set

The Catholic University of Korea, Seongdong, Not set

Severance Hospital, Yonsei Uni, Seoul, Not set

Hospital Pulau Pinang, Pulau Pinang, Georgetown

Hospital Sultanah Aminah Johor Bahru, Johor Bahru, Johor

Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan

Sarawak General Hospital, Kuching, Sarawak

Hospital Ampang, Ampang, Selangor

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Sl, Slupsk, Pomorskie

Ars Medical Sp. z o.o., Piła, Wielkopolskie

Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie

Wojewodzki Szpital Specjalistyczny, Biała Podlaska, Not set

Pratia Onkologia Katowice, Katowice, Śląskie

CCA-Braga. Centro Clínico Académico - Hospital Braga, Braga, Not set

CHUC - Centro Hospitalar e Universitário de Coimbr, Coimbra, Not set

Instituto Português de Oncologia de Lisboa, Lisboa, Not set

Centro Clinico Fundacao Champalimaud, Lisboa, Not set

H. São Francisco Xavier-Centro, Lisboa, Not set

H. Santa Maria. Centro Hospita, Lisboa, Not set

MONIKI - Oncology, Moscow, Moskovskaya Oblast'

MUZ City Clinical Hospital # 2, Novosibirsk, Novosibirskaya Oblast'

Tula Regional Clinical Hospital, Tula, Tul'skaya Oblast'

Budgetary Healthcare Institution of Omsk Region, Omsk, Not set

V.A. Almazov National Medical Research Center, Saint Petersburg, Not set

First Saint-Petersburg State Medical University n., Saint-Petersburg, Not set

GOU VPO Saratov State Medical University n.a. V.I., Saratov, Not set

National University Cancer Institute (NCIS), Singapore, Central Singapore

Singapore General Hospital, Singapore, Central Singapore

Institut Català d'Oncologia-Ho, Badalona, Barcelona

C.S. Parc Tauli, Sabadell, Barcelona

Hospital Universitario de Gran, Las Palmas de Gran Canaria, Canarias

H. Comarcal Costa del Sol, Málaga, Marbella

H.U. Ribera de Alzira, Alzira, Valencia

H.G.U. Alicante, Alicante, Not set

H. San Pedro de Alcántara, Cáceres, Not set

ICO-Hospital Universitari de G, Girona, Not set

Hospital Universitario Virgen, Granada, Not set

Hospital Universitario Fundaci, Madrid, Not set

Hospital U. 12 Octubre, Madrid, Not set

H.U. La Paz, Madrid, Not set

H.U.V. de la Victoria, Málaga, Not set

Hospital Universitario de Salamanco, Salamanca, Not set

Hospital Universitario Doctor, Valencia, Not set

H. Quirón Zaragoza, Zaragoza, Not set

Chang Gung Medical Foundation, Chiayi City, Chiayi

China Medical University Hospital - Hematology/Onc, Taichung City, Not set

Tri-Service General Hospital, Taipei, Not set

Medical Park Mersin Hastanesi, Mersin, Içel

Sakarya Research and Training Hospital - Medical Oncology, Adapazarı, Not set

Gazi University Medical Faculty, Ankara, Not set

Ankara University Medical Facu, Ankara, Not set

Istanbul üniversitesi cerrahpaşa, Istanbul, Not set

Medipol Bagcilar Mega Hospital, Istanbul, Not set

Marmara university pendik training and research hospital, Istanbul, Not set

Ege Universitesi Tip Fakultesi, Izmir, Not set

Mersin University Medical Faculty, Yenisehir/Mersin, Not set

Maidstone Hospital, Maidstone, Kent

St Bartholomew's Hospital, London, Not set

Guys and St Thomas' Hospital, London, Not set

Oxford University Hospitals, Oxford, Not set

Conditions: Myelofibrosis

Learn More ›

An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms

NCT05123365

Recruiting

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/06/2025

Locations: University of California, Irvine, Irvine, California +1 locations

Conditions: Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis

Learn More ›

A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806

Recruiting

The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: City of Hope - Duarte Main Site, Duarte, California +47 locations

City of Hope - Duarte Main Site, Duarte, California

Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia, Maryland

Weill Cornell Medicine NewYork-Presbyterian, New York, New York

Duke University, Durham, North Carolina

Cleveland Clinic, Cleveland, Ohio

Huntsman Cancer Institute, Salt Lake City, Utah

UZ Gent, Gent, Not set

UZ Leuven - Campus Gasthuisberg, Leuven, Not set

University Multiprofile Hospital for Active Treatment Sveti George - Base 1, Plovdiv, Not set

University Hospital Sv.Ivan Rilski - Sofia, Sofia, Not set

University Multiprofile Hospital for Active Treatment Aleksandrovska, Sofia, Not set

Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia, Sofia, Not set

University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD Department of Clinical Hematology, Stara Zagora, Not set

Research Institute of the McGill University Health Centre, Montreal, Quebec

CHU Tours, Hôpital Bretonneau Service d'Hématologie thérapie cellulaire, Tours Cedex 01, Indre-et-Loire

Chu De Nîmes - Institut De Cancérologie Du Gard, Nîmes, Occitanie

Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire

Centre Hospitalier Lyon-Sud, Pierre Bénite, Rhone-Alpes

Hôpital Saint-Louis, Paris, Not set

Hôpital Cochin, Paris, Not set

Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, Not set

Marien Hospital Düsseldorf, Düsseldorf, Not set

University Hospital Jena, Jena, Not set

Semmelweis Egyetem, Budapest, Not set

Hematology Division, Mauriziano Hospital, University of Turin, Orbassano, Torino

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Not set

IRCCS Ospedale Policlinico San Martino, Genova, Not set

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST, Meldola, Not set

Istituto Europeo di Oncologia, Milano, Not set

Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milan, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Università Campus Bio-Medico di Roma, Rome, Not set

Severance Hospital, Seoul, Seoul Teugbyeolsi

Seoul St. Mary's Hospital, The Catholic University of Korea, Seocho-gu, Seoul

Pusan National University Hospital, Busan-si, Not set

Spaarne Gasthuis, Hoofddorp, Not set

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Not set

AIDPORT, Skórzewo, Not set

Medicover Clinical Integrated Systems Sp. z o.o., Toruń, Not set

Coltea - Spital Clinic, Bucharest, Not set

Spitalul Filantropia - Craiova, Craiova, Not set

Hospital Universitario Central de Asturias, Oviedo, Asturias

Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia

Hospital San Pedro de Alcantara, Cáceres, Not set

Institut Català d'Oncologia Girona, Girona, Not set

Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas De Gran Canaria, Not set

Complejo Asistencial Universitario de Salamanca - Hospital Clínico, Salamanca, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

Conditions: Myelofibrosis, Moderate Thrombocytopenia

Learn More ›

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

Recruiting

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Gender:

ALL

Ages:

60 years and below

Trial Updated:

02/03/2025

Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes

Learn More ›

Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

NCT04562389

Recruiting

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: UAB Division of Hematology/Oncology, Birmingham, Alabama +148 locations

UAB Division of Hematology/Oncology, Birmingham, Alabama

UCLA - Satellite Site, Beverly Hills, California

City of Hope, Duarte, California

UCLA - Satellite Site, Encino, California

City of Hope - Irvine Lennar - Satellite, Irvine, California

UCLA, Los Angles, California

The Oncology Institute of Hope & Innovation, Pasadena, California

USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado

Smilow Cancer Hospital - New Haven, New Haven, Connecticut

Norton Cancer Institute - Saint Matthews, Louisville, Kentucky

Maryland Oncology Hematology-Satellite, Annapolis, Maryland

The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Maryland Oncology Hematology-Satellite, Brandywine, Maryland

Maryland Oncology Hematology, Columbia, Maryland

Maryland Oncology Hematology-Satellite, Rockville, Maryland

Maryland Oncology Hematology-Satellite, Silver Spring, Maryland

The Cancer & Hematology Centers -Satellite Site, Grand Rapids, Michigan

The Cancer & Hematology Centers of Muskegon, Norton Shores, Michigan

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Mount Sinai Health System, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Duke Cancer Institue, Durham, North Carolina

USOR - Oncology Hematology Care - Kenwood, Cincinnati, Ohio

OhioHealth, Columbus, Ohio

Vanderbilt Ingram Cancer Center, Nashville, Tennessee

Texas Oncology, Dallas, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

USOR - Virginia Cancer Specialists - Gainesville Office, Gainesville, Virginia

VCU Massey Cancer Center, Richmond, Virginia

USOR - Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia

Fred Hutchinson Cancer Center - SCAA South Lake Union, Seattle, Washington

West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, West Virginia

University of Wisconsin - Madison, Madison, Wisconsin

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Flemish Brabant

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan, Brugge, West-Vlaanderen

ZNA Stuivenberg - Satelite, Antwerpen, Not set

ZNA Stuivenberg, Antwerpen, Not set

University Multiprofile Hospital for Active Treatment Sveti George - Base 1, Plovdiv, Not set

University Multiprofile Hospital for Active Treatment Aleksandrovska, Sofia, Not set

University Multiprofile Hospital for Active Treatment St. Ivan Rilski, Sofia, Not set

Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia, Sofia, Not set

University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich, Stara Zagora, Not set

University of Alberta Hospital, Edmonton, Alberta

Research Institute of the McGill University Health Centre, Montreal, Quebec

Vseobecna Fakultni Nemocnice v Praze, Praha 2, Prague

Fakultní Nemocnice Hradec Králové, Hradec Králové, Not set

Fakultní Nemocnice Olomouc, Olomouc, Not set

Aarhus Universitetshospital, Aarhus N, Midtjylland

Tang Severinsen, Marianne, Aalborg, Nordjylland

Institut Bergonié, Bordeaux, Aquitaine

Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Aubergne

Hôpital Morvan, Brest, Bretagne

Chu De Nîmes - Institut De Cancérologie Du Gard, Nimes, Gard

Hôpital Emile Muller, Mulhouse, Grand Est

Hôpital Huriez, Lille, Hauts-de-France

Hôpital Universitaire Pitié Salpêtrière, Paris, Ile-de-France

Hôpital Bretonneau, Tours Cedex, Indre-et-Loire

Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, Loire

Hôpital l'Archet - CHU Nice, Nice Cedex 3, Paca

Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire

Centre Hospitalier Lyon-Sud, Pierre-Bénite, Rhone-Alpes

Hôpital Saint-Louis, Paris, Not set

Kliniken Ostalb - Stauferklinikum Schwäbisch Gmünd, Mutlangen, Baden-Württemberg

Marien Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen

Universitätsklinikum Halle, Halle, Sachsen-Anhalt

Städtisches Krankenhaus Kiel, Kiel, Schleswig-Holstein

Universitätsklinikum Jena, Jena, Thuringen

Laiko General Hospital of Athens, Athens, Attica

University General Hospital Attikon, Athens, Attica

General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Central Macedonia

University General Hospital of Larissa, Hematology Department, Larissa, Thessaly

Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház, Győr, Gyor-Moson-Sopron

Semmelweis Egyetem, Budapest, Not set

Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Central District

The Chaim Sheba Medical Center, Ramat Gan, Central District

Rambam Health Care Campus, Haifa, Haifa District

Carmel Medical Center, Haifa, Haifa District

Hadassah University Hospital - Mount Scopus - Satellite Site, Jerusalem, Jerusalem District

Hadassah University Hospital Ein Kerem, Jerusalem, Jerusalem District

Emek Medical Center, Afula, Northern District

Western Galilee Hospital-Nahariya, Nahariya, Northern District

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena

IRCCS Ospedale Policlinico San Martino, Genova, Genoa

Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milano, Milan

Istituto Europeo di Oncologia, Milano, Milan

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Milan

Fondazione IRCCS San Gerardo dei Tintori, Monza, Monza and Brianza

IRCCS Centro di Riferimento Oncologico di Basilicata, Rionero In Vulture, Potenza

Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Turin

Università Campus Bio-Medico di Roma, Rome, Viterbo

Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliero - Universitaria Careggi, Firenze, Not set

Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Not set

Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Not set

Centro Ricerche Cliniche di Verona, Verona, Not set

Pusan National University Hospital, Busan Gwang'yeogsi [Pusan-Kwangyokshi], Not set

Kyungpook National University Hospital, Daegu, Not set

Chonnam National University Hwasun Hospital, Hwasun-gun, Not set

Seoul National University Bundang Hospital, Seongnam-si Gyeonggido [Kyonggi-do], Not set

Samsung Medical Center, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, Not set

Universitair Medisch Centrum Groningen, Groningen, Not set

Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku, Wrocław, Dolnoslaskie

Medicover Integrated Clinical Services (MICS) - Centrum Medyczne Toruń, Toruń, Kujawsko-Pomorskie

Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie

Szpital Specjalistyczny w Brzozowie - Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza, Brzozów, Podkarpackie

Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdańsk, Pomorskie

Pratia Onkologia Katowice, Katowice, Slaskie

Specjalistyczny Szpital im. dra Alfreda Sokołowskiego w Wałbrzychu, Wałbrzych, Slaskie

AIDPORT, Skórzewo, Wielkopolskie

Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj

Spitalul Filantropia - Craiova, Craiova, Dolj

Institutul Regional De Oncologie Iasi, Moldova, Iasi

Spitalul Clinic Judetean De Urgenta Târgu Mureș, Târgu Mureş, Mureș

Coltea - Spital Clinic, Bucuresti, Not set

Spitalul Clinic Colentina, Bucuresti, Not set

Hospital Universitario Central de Asturias, Oviedo, Asturias

Institut Català d'Oncologia Badalona, Badalona, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Institut Català d'Oncologia Girona (ICO Girona), Girona, Not set

Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Not set

Hospital Universitario Lucus Augusti, Lugo, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Complejo Asistencial Universitario de Salamanca - Hospital Clínico, Salamanca, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

China Medical University Hospital, Taichung City, Taichung

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Not set

Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Not set

National Taiwan University Hospital, Taipei City, Not set

Chang Gung Memorial Hospital - Linkou Branch, Taoyuan, Not set

Guy's and St Thomas' NHS Foundation Trust, London, England

Oxford University Hospitals NHS Foundation Trust, Oxford, England

United Lincolnshire Hospitals NHS Trust-Satellite Site, Boston, Not set

United Lincolnshire Hospitals NHS Trust, Boston, Not set

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set

Imperial College Healthcare NHS Trust, London, Not set

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Not set

Conditions: Myelofibrosis

Learn More ›

Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ AML, MF and CMML (HSCT 002)

NCT05233618

Recruiting

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

01/30/2025

Locations: Danyelle Coley, Charlottesville, Virginia

Conditions: Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia

Learn More ›

A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis

NCT04176198

Recruiting

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: University of Alabama, Birmingham, Alabama +60 locations

University of Alabama, Birmingham, Alabama

The University of Arizona Cancer Center, Tucson, Arizona

City of Hope, Duarte, California

University of Southern California, Los Angeles, California

Hoag Family Cancer Institute, Newport Beach, California

Blood Cancer Center, Denver, Colorado

University of Florida Health Shands Cancer Hospital, Gainesville, Florida

University of Miami, Miami, Florida

Emory University, Atlanta, Georgia

University of Chicago, Chicago, Illinois

University of Maryland, Baltimore, Maryland

University of Michigan, Ann Arbor, Michigan

University of Minnesota, Minneapolis, Minnesota

Washington University of Medicine, Saint Louis, Missouri

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Montefiore Cancer Center, Bronx, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Weill Cornell Medical Center, New York, New York

Duke Cancer Institute, Durham, North Carolina

Ohio State University, Columbus, Ohio

Tri-Star Centennial Medical Center, Nashville, Tennessee

Vanderbilt University, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

University of Washington - Fred Hutchinson Cancer Center, Seattle, Washington

Royal Adelaide Hospital, Adelaide, South Australia

Eastern Health Box Hill Hospital, Box Hill, Victoria

Monash University, Clayton, Victoria

Icon Cancer Centre (Ashford Cancer Centre Research), Adelaide, Not set

University Hospitals Leuven, Leuven, Vlaams-Brabant

ZNA Cadix, Antwerp, Not set

ZNA Middelheim, Antwerp, Not set

University of British Columbia, Vancouver, British Columbia

Princess Margaret Cancer Center, Toronto, Ontario

Centre Hospitalier Universitaire D'Amiens, Amiens, Not set

Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet, Nice, Not set

Institut de cancerologie du Gard, Nimes, Not set

Hospital Saint Louis, Paris, Not set

Institut Gustave Roussy, Villejuif, Not set

IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia, Bologna, Not set

ASST - Spedali Civili di Brescia, Brescia, Not set

IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori", Meldola, Not set

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Not set

Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino, Torino, Not set

Aichi Medical University Hospital, Aichi, Not set

National Cancer Center Hospital East, Chiba, Not set

Kyushu University Hospital, Fukuoka, Not set

Hokkaido University Hospital, Hokkaido, Not set

University of Miyazaki Hospital, Miyazaki, Not set

Okayama University Hospital, Okayama, Not set

Osaka University Hospital, Osaka, Not set

Saitama Medical Center, Saitama, Not set

Tohoku University Hospital, Sendai, Not set

Shizuoka Cancer Center, Shizuoka, Not set

Juntendo University Hospital, Tokyo, Not set

Mie University Hospital, Tsu, Not set

United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital, Lincoln, Not set

University College London Hospital's NHS foundation Trust, London, Not set

Conditions: Myelofibrosis

Learn More ›

Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

NCT05037760

Recruiting

This is a Phase 2, multicenter, open-label study to evaluate the safety and efficacy of KER-050 as monotherapy or in combination with ruxolitinib in participants with Myelofibrosis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Fred Hutchinson Cancer Center, Seattle, Washington +46 locations

Fred Hutchinson Cancer Center, Seattle, Washington

Concord Hospital, Concord, New South Wales

The Tweed Hospital, Tweed Heads, New South Wales

Flinders Medical Centre, Woodville South, South Australia

St. Vincent's Hospital Melbourne, Fitzroy, Victoria

Royal Melbourne Hospital, Melbourne, Victoria

Ballarat Oncology & Hematology Service, Wendouree, Victoria

Hospital de Clinicas de Porto Alegre, Porto Alegre, Not set

IMV Pesquisa Cardiologica Sociedade Simples, Porto Alegre, Not set

Albert Einstein Sociedade Beneficente Israelita Brasiliera, São Paulo, Not set

Hospital Beneficencia Portuguesa de Sao Paulo, São Paulo, Not set

Hospital das Clínicas FMUSP: HC, São Paulo, Not set

Instituto de Ensino e Pesquisas Sao Lucas, São Paulo, Not set

CHU Amiens - Hopital Sud, Amiens, Not set

Hôpital Morvan, Brest, Not set

Hopital Prive Sevigne, Cesson-Sévigné, Not set

Centre Hospitalier Lyon Sud, Lyon, Not set

Institut de Cancerologie du Gard, Nîmes, Not set

Hopital de la Source - CHR Orleans, Orléans, Not set

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Not set

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Not set

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Not set

Azienda Ospedaliera Universitaria Careggi, Firenze, Not set

Ospedale Policlinico San Martino, Genova, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Not set

Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Not set

Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Not set

Policlinico Universitario Fondazione Agostino Gemelli, Roma, Not set

Azienda Socio Sanitaria Territoriale Sette Laghi, Varese, Not set

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Not set

Gachon University Gil Medical Center, Incheon, Not set

Samsung Medical Center, Seoul, Not set

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Not set

Soonchunhyang University Seoul Hospital, Seoul, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Institut Català d'Oncologia Badalona - Hospital Universitari Germans Trias i Pujol, Barcelona, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario La Princesa, Madrid, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Hospital QuironSalud de Zaragoza, Zaragoza, Not set

Pilgrim Hospital, Boston, Not set

St. James Hospital, Leeds, Not set

Guy's Hospital, London, Not set

Hammersmith Hospital, London, Not set

University College London, London, Not set

Conditions: Myelofibrosis

Learn More ›

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548

Recruiting

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/12/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +5 locations

Conditions: Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis

Learn More ›

1 - 12 of 43